Effect of L-dopa on seborrhoea of Parkinsonism
Burton, J.L.; Shuster, S.
Lancet 2(7667): 311
1970
ISSN/ISBN: 0140-6736 PMID: 4194386 Document Number: 28211
Document emailed within 1 workday
Related Documents
Flatberg, P. 1970: 1-dopa for parkinsonism Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 90(10): 1102-1103Reveno, W.S.; Bauer, R.B.; Rosenbaum, H. 1973: L-dopa for parkinsonism Geriatrics 28(1): 86-88
Proniv, D.I.; Sirotina, O.S.; Bukhovtsev, P.P.; Mis'kiv, I.I. 1976: Use of the preparation L-dopa in parkinsonism Vrachebnoe Delo 1: 113-116
Court, J.; Kase, J.C.; Palacios, E.; Mena, I. 1971: Treatment of parkinsonism with L-dopa Revista Medica de Chile 99(6): 399-401
Hernández Peniche, J.; Martínez Villar, C.; De León Charles, C. 1971: Treatment of parkinsonism with L-dopa Revista de Investigacion Clinica; Organo del Hospital de Enfermedades de la Nutricion 23(2): 125-132
Leickert, K.H. 1971: Historical notes on parkinsonism and L-Dopa Die Medizinische Welt 33: 1278-1279
Jörg, J. 1975: Therapy of parkinsonism using L-Dopa (Brocadopa) Die Medizinische Welt 26(3): 124-126
Danielczyk, W.; Korten, J.J. 1971: Action of amantadine HCl alone and in combination with L-dopa on parkinsonism Medizinische Monatsschrift 25(10): 472-479
Stoof, J.C.; Koetsier, J.C. 1974: Implications of the formulation of m-tyrosine from DOPA for Parkinsonism Nederlands Tijdschrift Voor Geneeskunde 118(23): 900
Sánchez Longo, L.P.; Cruz de León, C.; Rodríguez del Valle, J.; Hernández Ortiz, T. 1971: The history of the discovery of L-dopa as treatment in parkinsonism Boletin de la Asociacion Medica de Puerto Rico 63(2): 36-40
Bhaskar, P.A.; Bhaskar, E.A.; Jagannathan, K. 1975: Augmenting procedures during L-dopa therapy for Parkinsonism Journal of the Association of Physicians of India 23(1): 21-27
Sweet, R.D.; McDowell, F.H. 1974: The "on-off" response to chronic L-DOPA treatment of Parkinsonism Advances in Neurology 5: 331-338
Sandler, M. 1972: L-dopa metabolism in man (with special reference to parkinsonism) Scientific Basis of Medicine Annual Reviews 1972: 161-173
Rondot, P.; Ziegler, M. 1983: Dystonia--L-dopa responsive or juvenile parkinsonism? Journal of Neural Transmission. Supplementum 19: 273-281
Stammler, A.; Vielhaber, K. 1972: Therapy of Parkinsonism using L-dopa in combination with a decarboxylase inhibitor Fortschritte der Neurologie Psychiatrie und Ihrer Grenzgebiete 40(10): 564-568
Marjerrison, G.; Boulton, A.A.; Rajput, A. 1971: Dopa therapy in parkinsonism effects on the EEG and amine metabolism Internationale Zeitschrift für Klinische Pharmakologie Therapie und Toxikologie. International Journal of Clinical Pharmacology Therapy and Toxicology 4(2): 263-266
Garde, K.; Kruse-Larsen, C. 1971: Postmenopausal vaginal haemorrhage as a complication of treatment of Parkinsonism with L-dopa Ugeskrift for Laeger 133(18): 886-887
Yahr, M.D.; Duvoisin, R.C.; Mendoza, M.R.; Schear, M.J.; Barrett, R.E. 1971: Modification of L-dopa therapy of Parkinsonism by alpha-methyldopa hydrazine (MK-486) Transactions of the American Neurological Association 96: 55-58
Megna, G.; Pennetta, R.; Andreula, C. 1977: Clinical and psychometric observations on the use of S-adenosylmethionine in parkinsonism during chronic L-dopa treatment Acta Neurologica 32(2): 204-217
Ferraris, M. 1971: Psychological status of patients with Parkinsonism during treatment with amantadine hydrochloride and L-Dopa Minerva Medica 62(82): 3971-3973